Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (NCT07227415)
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
🩺 Plain-English Summary (8th-Grade Level)
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Building- Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (128 Sites)
Showing the first 25 of 128 sites.
- Mayo Clinic Building- Phoenix — Phoenix, Arizona
- Mayo Clinic Arizona — Scottsdale, Arizona
- Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- City of Hope Investigational Drug Services (IDS) — Duarte, California
- UC San Diego Medical Center - Encinitas — Encinitas, California
- City of Hope Investigational Drug Services (IDS) — Irvine, California
- City of Hope — Irvine, California
- UC San Diego / Moores Cancer Center — La Jolla, California
- UC San Diego Koman Family Outpatient Pavilion — La Jolla, California
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California
- UC San Diego Sulpizio Cardiovascular Center — La Jolla, California
- City of Hope — Long Beach, California
- UC San Diego Medical Center - Bankers Hill — San Diego, California
- UC San Diego McGrath Outpatient Pavilion - Hillcrest — San Diego, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- UC San Diego Medical Center - Rancho Bernardo — San Diego, California
- City of Hope UPLAND — Upland, California
- UC San Diego Medical Center - Vista — Vista, California
- Rocky Mountain Cancer Centers, LLP — Denver, Colorado
- Mayo Clinic Pharmacy — Jacksonville, Florida
- Orlando Health Ambulatory Care Center — Orlando, Florida
- Orlando Health Cancer Institute — Orlando, Florida
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Renal Cell
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) — San Francisco, California
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) — Chandler, Arizona
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) — San Francisco, California
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) — Birmingham, Alabama
- A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) — Phoenix, Arizona
- Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) — Durham, North Carolina
Explore by condition: All Carcinoma, Renal Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.